Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial

被引：4
|
作者：
Cafferkey, C. [1 ]
Smyth, E. [1 ]
Loehr, A. [2 ]
Harding, T. [3 ]
Raponi, M. [2 ]
Okines, A. [1 ]
Waddell, T. [1 ]
Chau, I. [1 ]
Cunningham, D. [1 ]
机构：
[1] Royal Marsden Hosp NHS Fdn Trust, GI & Lymphoma Unit, London, England
[2] Clovis Oncol, Mol Diagnost, San Francisco, CA USA
[3] Clovis Oncol, Preclin Res & Translat Med, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw371.41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
649P
引用
收藏
页数：1
相关论文
共 8 条
  • [1] A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
    Waddell, Tom Samuel
    Chau, Ian
    Barbachano, Yolanda
    de Castro, David Gonzalez
    Wotherspoon, Andrew
    Saffery, Claire
    Middleton, Gary William
    Wadsley, Jonathan
    Ferry, David Raymond
    Mansoor, Wasat
    Crosby, Tom David Lewis
    Coxon, Fareeda Y.
    Smith, David
    Waters, Justin S.
    Iveson, Timothy
    Falk, Stephen
    Slater, Sarah
    Okines, Alicia Frances Clare
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] A RANDOMISED MULTICENTRE TRIAL OF EPIRUBICIN, OXALIPLATIN AND CAPECITABINE (EOC) plus PANITUMUMAB IN ADVANCED OESOPHAGO-GASTRIC CANCER (REAL3): UPDATED RESULTS
    Waddell, T. S.
    Reis-Filho, J.
    Gonzalez-De-Castro, D.
    Chau, I.
    Wotherspoon, A.
    Gupta, S.
    Saffery, C.
    Middleton, G.
    Wadsley, J.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 224 - 224
  • [3] Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.
    Waddell, Tom Samuel
    Chau, Ian
    Peckitt, Clare
    Gonzalez, David
    Wotherspoon, Andrew
    Patel, Bijal
    Middleton, Gary William
    Wadsley, Jonathan
    Ferry, David
    Mansoor, Wasat
    Crosby, Tom David Lewis
    Coxon, Fareeda Y.
    Smith, David
    Waters, Justin S.
    Iveson, Timothy
    Falk, Stephen
    Slater, Sarah
    Okines, Alicia Frances Clare
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    Waddell, Tom
    Chau, Ian
    Cunningham, David
    Gonzalez, David
    Frances, Alicia
    Okines, Clare
    Wotherspoon, Andrew
    Saffery, Claire
    Middleton, Gary
    Wadsley, Jonathan
    Ferry, David
    Mansoor, Wasat
    Crosby, Tom
    Coxon, Fareeda
    Smith, David
    Waters, Justin
    Iveson, Timothy
    Falk, Stephen
    Slater, Sarah
    Peckitt, Clare
    Barbachano, Yolanda
    LANCET ONCOLOGY, 2013, 14 (06): : 481 - 489
  • [5] REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.
    Chau, I.
    Okines, A. F. C.
    de Castro, D. Gonzalez
    Saffery, C.
    Barbachano, Y.
    Wotherspoon, A.
    Puckey, L.
    Wilson, S. Hulkki
    Coxon, F. Y.
    Middleton, G. W.
    Ferry, D. R.
    Crosby, T. D. L.
    Madhusudan, S.
    Wadsley, J.
    Waters, J. S.
    Hall, M.
    Swinson, D.
    Robinson, A.
    Smith, D.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial (vol 14, pg 481, 2013)
    Waddell, Tom
    Chau, Ian
    Cunningham, David
    Gonzalez, David
    Okines, Alicia Frances Clare
    Wotherspoon, Andrew
    Saffery, Claire
    Middleton, Gary
    Wadsley, Jonathan
    Ferry, David
    Mansoor, Wasat
    Crosby, Tom
    Coxon, Fareeda
    Smith, David
    Waters, Justin
    Iveson, Timothy
    Falk, Stephen
    Slater, Sarah
    Peckitt, Clare
    Barbachano, Yolanda
    LANCET ONCOLOGY, 2013, 14 (07): : E254 - E254
  • [7] Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
    Okines, Alicia F. C.
    Ashley, Sue E.
    Cunningham, David
    Oates, Jacqueline
    Turner, Andrea
    Webb, Janine
    Saffery, Claire
    Chua, Yu Jo
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3945 - 3950
  • [8] Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C
    Burtness, Barbara
    Lee, Ju-Whei
    Yang, Donghua
    Zhu, Fang
    Garcia, Joaquin J.
    Forastiere, Arlene A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
1